# Nurix Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nurix-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.nurixtx.com
- Total disclosed funding: $125M
- Latest round: Series D (Mar 9, 2020)
- Investors on record: 8

## About

Based in the US, Nurix Therapeutics, Inc. is a biotechnology company focused on developing innovative medicines through targeted protein degradation technology, addressing significant unmet medical needs in oncology and autoimmune diseases.Founded in 2012 in San Francisco, US, Nurix Therapeutics, Inc. specializes in leveraging protein degradation technology for drug development. The company has undergone strategic funding rounds, including a notable IPO in July 2020, raising USD 209 mn. Michael Rape is the founder, and Arthur Sands serves as CEO. The company has completed 9 deals, with the latest funding round being a Private Placement/Follow on in July 2022, which raised USD 40 mn.Nurix Therapeutics specializes in the development of innovative medicines that leverage targeted protein degradation technology to combat various diseases, particularly cancers and autoimmune disorders. Their primary offerings include degraders and Degrader-Antibody Conjugates (DACs), which are engineered to eliminate disease-causing proteins by utilizing the natural protein degradation processes of cells. These products aim to deliver enhanced precision and improved safety in treatment outcomes, thus addressing unmet medical needs in oncology and immunology. The company’s products are marketed primarily in North America and Europe, focusing on patient populations suffering from chronic lymphocytic leukemia and other malignancies, as well as autoimmune diseases.For the year 2023, Nurix Therapeutics reported revenue of USD 76.99 mn, with an EBITDA of USD -147.53 mn. The company generates revenue through strategic partnerships, collaborations, and clinical trial funding, structured around licensing agreements with pharmaceutical companies and research institutions seeking to utilize their targeted protein degradation platform.Nurix Therapeutics is focused on expanding its product portfolio and market presence. The recent funding of USD 40 mn raised in July 2022 will support the development and clinical advancement of new therapeutics. The company aims to introduce additional targeted therapies to the market by 2025 and plans to expand its operations into Europe and Asia by identifying partners in those regions. Additionally, with a strong pipeline including products like NX-5948, Nurix is positioned to enhance its offering in treating serious health conditions.

## Funding rounds

- Series D, Mar 9, 2020, $120M — Bain Capital, The Column Group, Wellington Management, Third Rock Ventures, Foresite Capital, Redmile Group, EcoR1 Capital, Boxer Capital
- Series B, Dec 18, 2013, $2.1M — The Column Group, Third Rock Ventures
- Seed, May 17, 2012, $3.1M — The Column Group, Third Rock Ventures

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Seed, Series B, Series D
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Seed, Series B, Series D
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series D
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series D
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series D
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series D
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series D